Who
Johanna Mercier
Chief Comm & Corp Aff Officer
Company insider
Files Form 4 as: Chief Comm & Corp Aff Officer, Gilead Sciences; Director, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 234
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $46.7M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 24 Jul 2019
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $469K3,000 at $156.22 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $230K1,600 at $143.69 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $116K800 at $144.46 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $87K600 at $145.29 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $230K1,600 at $143.69 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $116K800 at $144.46 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $87K600 at $145.29 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $195K1,347 at $144.81 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $195K1,347 at $144.81 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $1.5M23,110 at $66.64 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $137K1,890 at $72.34 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $2.3M16,530 at $137.37 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,110 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,890 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.6M11,470 at $138.04 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,110 at $0.00 | filing |
News
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026
0 headlines in the last 90 days name Johanna Mercier; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.